New hope for kids with tough neuroblastoma: drug combo aims to shrink tumors
NCT ID NCT05027386
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called apatinib combined with two chemotherapy drugs (irinotecan and temozolomide) in children aged 5 to 18 with neuroblastoma that has returned or not improved after standard treatment. The goal is to see if the combination can shrink tumors and help children live longer. About 125 children will take part across multiple hospitals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yizhuo Zhang
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a shorter chemo combo tame High-Risk neuroblastoma?
- Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
- Can AI read tumor slides to outsmart childhood cancer?
- Can a radioated molecule shrink untreatable neuroblastoma?
- Slowing down immunotherapy infusion may reduce pain in children with Tough-to-Treat neuroblastoma